Could a cancer drug boost radiation for rare sarcomas?

NCT ID NCT02787642

Completed Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether adding the drug olaparib to standard radiation therapy is safe for people with advanced soft-tissue sarcoma that cannot be removed by surgery. 41 participants received olaparib pills alongside daily radiation for about 7.5 weeks. The main goals were to find the highest safe dose and to check for serious side effects. This study does not yet prove the combination works better than radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (a drug that may make cancer cells more sensitive to radiation)
What this could lead to: If successful, this could point toward a new way to treat advanced soft-tissue sarcoma by combining a targeted drug with standard radiation.
What could go wrong: This is an early Phase 1 trial with only 41 participants, focused on safety and dosing. It is not yet known if the combination works better than radiation alone, and there may be serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69373, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud - IUCT

Toulouse, 31052, France
Institut du Cancer de Montpellier

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.